Physician profile

Harinder K Bisla

Internal Medicine · Roseville, CA

NPI 1174512685

$4,444.39

in general payments reported to CMS, 2019-2025

43 companies · $281 in 2025

The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

See the full distribution for Internal Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,478.97
Education$64.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $515.83 2019-2025 Ozempic, Rybelsus
Abbvie INC. $510.37 2021-2023 Vraylar, Ubrelvy, Linzess
Glaxosmithkline, LLC. $491.03 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Astrazeneca Pharmaceuticals LP $331.46 2019-2024 Breztri, Farxiga
Allergan, INC. $309.32 2019-2020
Lilly USA, LLC $264.68 2020-2025 Mounjaro, Kisunla, Trulicity
Boehringer Ingelheim Pharmaceuticals, INC. $239.18 2019-2022
Pfizer INC. $216.92 2019-2025
Amgen INC. $197.35 2020-2024 Prolia, Evenity
Novartis Pharmaceuticals Corporation $99.48 2022-2024
Janssen Pharmaceuticals, INC $97.76 2019-2024 Spravato
E.R. Squibb & Sons, L.L.C. $97.33 2019-2022
Merck Sharp & Dohme LLC $96.97 2020-2021
Exact Sciences Corporation $81.73 2023-2025 Cologuard Collection Kit
Sanofi-Aventis U.S. LLC $75.58 2019-2020
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $64.99 2023
Vanda Pharmaceuticals INC. $59.91 2020-2021
Biohaven Pharmaceutical Holding Company LTD. $51.04 2022
Mayne Pharma Commercial LLC $49.64 2023-2025
Eisai INC. $40.16 2020
Ibsa Pharma INC. $39.52 2021-2023 Tirosint, Licart
Scilex Pharmaceuticals INC. $38.45 2019
Kowa Pharmaceuticals America, INC. $35.47 2019
Takeda Pharmaceuticals U.S.A., INC. $32.94 2019
Seqirus USA INC $31.69 2019-2025 Fluad, Flucelvax
Sanofi Pasteur INC. $31.29 2019-2020
Almatica Pharma LLC $30.43 2022
Ironwood Pharmaceuticals, INC $29.11 2021
Treace Medical Concepts, INC. $27.89 2023
Dexcom, INC. $27.18 2024 Dexcom G6 Transmitter
Esperion Therapeutics, INC. $26.03 2021
Amarin Pharma, INC. $25.40 2019-2020
Bausch Health US, LLC $24.64 2024 Aplenzin
Vifor Pharma, INC. $23.10 2019
Idorsia Pharmaceuticals US INC $20.98 2023 Quviviq
Hologic Sales and Service, LLC $18.27 2023 Aptima
Mimedx Group, INC. $16.54 2025
Boston Scientific Corporation $14.24 2020
Therapeuticsmd, INC. $14.14 2020
Amag Pharmaceuticals, INC. $14.05 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $12.90 2023 Xifaxan
Abbott Laboratories $11.50 2021
Phathom Pharmaceuticals, INC. $7.90 2025 Voquezna

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Harinder K Bisla

$4,444.39

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/234755/harinder-k-bisla

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.